• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Prostate cancer screening shows reduction in mortality after 13 year follow-up [ERSPC trial]

byMelissa McCoyandStefan Trela
August 8, 2014
in Chronic Disease, Oncology, Urology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Prostate cancer screening showed a continued reduction in prostate cancer incidence and mortality after a longer follow-up of 13 years compared to previous results after 9 and 11 years.

2. The absolute effect of screening was substantially increased after 13 years of follow-up, demonstrated by a reduction in the number needed to invite for screening to prevent one cancer death and the number needed to detect cancer from values after 9 and 11 years. 

Evidence Rating Level: 1 (Excellent)       

Study Rundown: Screening for prostate cancer has been shown to significantly reduce prostate cancer mortality but is still controversial due to potential overdiagnosis leading to overtreatment and side effects. The European Randomised study of Screening for Prostate Cancer (ERSPC) began in 1993, and included 162,388men aged 50-74 from the Netherlands, Belgium, Sweden, Finland, Italy, Spain, Switzerland and France. To assess the affect of prostate cancer screening on mortality from prostate cancer, participants were either screened for prostate cancer or underwent no intervention. Previous follow-up results from 9 and 11 years showed a significant reduction in prostate cancer mortality. This study presented updated results including follow-up after 13 years.

The study showed that screening resulted in a continued decrease in prostate cancer incidence and mortality after a longer follow-up of 13 years compared to 9 years. The number needed to invite for screening to prevent one cancer death and the number needed to detect cancer substantially decreased with a longer follow-up as well. This analysis is strong as a long-standing study with a high enrollment of participants. Limitations include contamination in the control group and relatively short follow-up. The authors conclude that prostate cancer screening significantly reduces prostate cancer mortality with an increased effect seen after 13 years compared to 9 and 11 years. Despite these findings, further analysis of harm reduction is still required before the introduction of population-based screening for prostate cancer.

Click to read the study in The Lancet

Relevant Reading: Randomised prostate cancer screening trial: 20 year follow-up

RELATED REPORTS

Pelvic lymph node radiotherapy and androgen deprivation therapy augment progression-free status following prostatectomy

Abiraterone plus prednisone improves survival in patients with de novo metastatic castration-sensitive prostate cancer

COVID-19 pandemic associated with reductions in delivery of cancer care services in Ontario, Canada

In-Depth [randomized controlled trial]: The primary outcome of the study was prostate cancer mortality and analysis was based on intention to treat (or screen). Secondary analysis corrected for non-participation in the screening group. Results were collected after a follow-up period of 13 years and the values were compared to those collected after 9 and 11 years of follow-up.

7,408 prostate cancer cases were diagnosed in the screening group and 6,107 in the non-intervention group. Prostate cancer incidence decreased in the screening group compared to the non-intervention group after a longer follow-up period, with an incidence rate ratio of 1.57 (95% Confidence Interval [CI] 1.51-1.62) after 13 years, compared to 1.66 (1.60-1.73) after 11 years and 1.91 (1.83-1.99) after 9 years. Prostate cancer mortality also decreased with screening, but the relative effect was mainly detected between 1-11 years, with little change during years 11-13. Mortality decreased by 21% after 13 years (Rate Ratio [RR] 0.79, 95% CI 0.69-0.91, p=0.001), compared to 22% after 11 years (0.78, 0.66-0.91) and 15% after 9 years (0.85, 0.70-1.03). After adjusting for non-participants in the screening group, mortality decreased by 27% after 13 years (0.73, 0.61-0.88, p<0.0007) compared to 29% after 11 years (0.79, 0.58-0.88, p=0.001).

The absolute effect of screening also showed a benefit with a longer follow-up period. The number needed to invite for screening to prevent one cancer death decreased to 781 after 13 years, from 979 after 11 years and 1,410 after 9 years. The number needed to screen to detect cancer decreased to 27 after 13 years, from 35 after 11 years and 48 after 9 years.

Image: PD

More from this author: Funding for antibiotic research in UK may be trailing behind resistance,Childhood tuberculosis incidence may be 25% higher than prior estimates, Adults with Asperger’s syndrome at increased risk for suicidal thoughts and behaviors, UK fails to reduce deaths of young people, Most comprehensive study to date reveals climbing worldwide obesity prevalence, Weight loss during adulthood linked with long-term cardiovascular benefits

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.  

 

Tags: cancer screeningprostateprostate cancer
Previous Post

Smoking bans in prisons associated with reduced prisoner mortality

Next Post

Centralized stroke care linked to improved mortality and reduced length of stay

RelatedReports

Patient-reported outcomes differ significantly based on treatment in prostate cancer: The ProtecT trial
Chronic Disease

Pelvic lymph node radiotherapy and androgen deprivation therapy augment progression-free status following prostatectomy

May 24, 2022
Patient-reported outcomes differ significantly based on treatment in prostate cancer: The ProtecT trial
Chronic Disease

Abiraterone plus prednisone improves survival in patients with de novo metastatic castration-sensitive prostate cancer

May 11, 2022
Chronic Disease

COVID-19 pandemic associated with reductions in delivery of cancer care services in Ontario, Canada

April 29, 2022
#VisualAbstract: Daprodustat noninferior to darbepoetin alfa in the treatment of anemia in patients with chronic kidney disease on incident dialysis
StudyGraphics

#VisualAbstract: Bone mineral density testing beneficial for older men receiving androgen deprivation therapy for localized or regional prostate cancer

April 13, 2022
Next Post
Patient transfers to trauma centers often unnecessary

Centralized stroke care linked to improved mortality and reduced length of stay

3D mammography (tomosynthesis) enhances accuracy of breast cancer screening

Mammography linked to improved breast cancer outcomes among women 75 and older

Lower vulvar cancer-related mortality in African Americans

One hour PTH levels may predict early post-thyroidectomy hypocalcemia

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Pelvic lymph node radiotherapy and androgen deprivation therapy augment progression-free status following prostatectomy
  • Operating the day after performing surgery the previous night not associated with adverse patient outcomes
  • Gratitude-focused writing may improve mental wellness during periods of chronic stress
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.